Karinza Phoenix

Myopharm Limited (Pre-IPO)

Advancing the Next Generation of Therapies for Metabolic and Inflammatory Diseases

Myopharm is an Australian clinical-stage biopharmaceutical company focused on developing innovative therapies that improve outcomes for patients living with metabolic and inflammatory diseases.

With a diversified portfolio spanning prescription drug candidates and clinically validated consumer health products, the Company is pursuing multiple pathways to create long-term shareholder value while addressing significant unmet medical needs.

As global demand for innovative healthcare solutions continues to grow, Myopharm is positioned at the convergence of scientific innovation, clinical development and commercial opportunity.

Myopharm is building strong momentum across its clinical and commercial programs, with several important updates expected across its pipeline and development initiatives.

Join Karinza Phoenix at Stocks in the Vines as she provides investors with an update on the Company's strategy, pipeline progress, upcoming milestones and the opportunities driving its next phase of growth.

For Karinza, the inspiration to build Myopharm came from recognising the growing impact of diabetes and the need for better treatment options for patients living with chronic disease. That insight helped drive the creation of Myopharm:

With a mission to develop innovative therapies that address significant unmet medical needs and improve patient outcomes.

At Stocks in the Vines 2026, Karinza shared with Peter Taylor the story behind Myopharm, the challenges and opportunities ahead, and why she believes innovation in healthcare has the potential to make a meaningful difference in people’s lives.

Watch the full interview to hear Karinza’s journey and vision for the future of Myopharm:

🚨 A must-watch interview for biotech investors. Karinza discusses the company’s upcoming IPO and why the business is strategically positioned within one of the fastest-growing segments of global healthcare. With increasing demand for GLP-1 related therapies and growing industry interest in combination treatments,

Myopharm is targeting a market experiencing rapid expansion and significant pharmaceutical attention.

Karinza also explains how looming patent expiries across major diabetes and metabolic disease treatments could create substantial opportunities for emerging innovators, potentially reshaping the competitive landscape over the coming years.

As global healthcare markets continue evolving, Myopharm is positioning itself to capitalise on these shifts through innovation, strategic timing and a growing market need:

Visit Myopharm